Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document

This Research Agreement (this “Agreement”) is entered into between Orexigen Therapeutics, Inc. with offices at 12481 High Bluff Drive, San Diego, CA 92130, hereinafter referred to as “SPONSOR”, and the Oregon Health & Science University, a non-profit, public corporation of the state of Oregon, located at 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, hereinafter referred to as “UNIVERSITY”.
WHEREAS, SPONSOR entered into a Research Agreement with UNIVERSITY effective July 14, 2003 to have UNIVERSITY perform the research services set forth in the scope of work (attached hereto as Attachment A) (“Research Agreement #1”); and
WHEREAS, it is anticipated that the term of Research Agreement #1 will expire prior to completion of the research set forth therein and the parties wish to continue the relationship to complete the research services requested under Research Agreement #1;
WHEREAS, SPONSOR also desires to have UNIVERSITY perform additional research services which are set forth in the scope of work (attached hereto as Attachment B);
WHEREAS, the performance of such research is consistent, compatible and beneficial to the academic role and mission of UNIVERSITY as an institution of higher education, and, in consideration of the mutual promises and covenants contained herein, the parties hereto agree to incorporate the terms of Research Agreement #1 into this Agreement so that the research services set forth in Attachment A and Attachment B may be performed pursuant to this Agreement on the terms and conditions as follows:
UNIVERSITY agrees to use all reasonable best efforts to perform for SPONSOR the research activities described in Attachment A and Attachment B, hereinafter, collectively, the “SCOPE OF WORK”, under the direction and supervision of Michael Cowley, PhD, hereinafter “PRINCIPAL INVESTIGATOR” or “PI”. UNIVERSITY agrees that during the term of this agreement the PI shall not conduct, direct, nor assist in other corporate-funded research or services directed toward screening, analysis, or development of therapeutic agents for the treatment of obesity.
This Agreement shall become effective as of May 1, 2006 (the “Effective Date”), and shall be shall be effective for a period of Two and One-half (2 1/2) years unless mutually agreed upon in writing between the parties.